Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

While the market for systemic lupus erythematosus (SLE) and lupus nephritis therapies remains dominated by generic drugs, the FDA has approved only a few targeted biologics, including GSK’s Benlysta ...

The factors contributing to the treatment efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in the maintenance phase are unknown. Here, we collected blood samples from patients ...

1 Department of Neurology, Peking University People’s Hospital, Beijing, China 2 Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China Background: ...